{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:20Z","timestamp":1793642360271,"version":"4.5.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Autism Dev Disord"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10803-012-1723-5","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T17:16:19Z","timestamp":1354641379000},"page":"1773-1783","source":"Crossref","is-referenced-by-count":116,"title":["Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Justine M.","family":"Kent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Karcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Ness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskaran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"issue":"6","key":"1723_CR1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","volume":"15","author":"MG Aman","year":"2005","unstructured":"Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., et al. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15(6), 869\u2013884.","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"1723_CR2","unstructured":"Aman, M. G., & Singh, N. N. (1994). Aberrant behavior checklist\u2014community. (supplementary manual). East Aurora, NY: Slosson Educational Publication."},{"issue":"5","key":"1723_CR3","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985a). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485\u2013491.","journal-title":"American Journal of Mental Deficiency"},{"issue":"5","key":"1723_CR4","first-page":"492","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985b). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89(5), 492\u2013502.","journal-title":"American Journal of Mental Deficiency"},{"key":"1723_CR5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.clinthera.2007.07.026","volume":"29","author":"MG Aman","year":"2007","unstructured":"Aman, M. G., Vinks, A. A., Remmerie, B., Mannaert, E., Ramadan, Y., Masty, J., et al. (2007). Plasma pharmacokinetics characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorder. Clinical Therapeutics, 29, 1476\u20131486.","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"1723_CR7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., et al. (2007). Effect of short- and long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry, 61(4), 545\u2013550.","journal-title":"Biological Psychiatry"},{"issue":"12","key":"1723_CR8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","volume":"42","author":"LE Arnold","year":"2003","unstructured":"Arnold, L. E., Vitiello, B., Mcdougle, C., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42(12), 1443\u20131450.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"1723_CR9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672\u2013676.","journal-title":"British Journal of Psychiatry"},{"issue":"11","key":"1723_CR11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling, R. L., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64(11), 1362\u20131369.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"1723_CR12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.mp.4001896","volume":"12","author":"CM Freitag","year":"2007","unstructured":"Freitag, C. M. (2007). The genetics of autistic disorders and its clinical relevance: A review of the literature. Molecular Psychiatry, 12(1), 2\u201322.","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"1723_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/104454604773840472","volume":"14","author":"A Gagliano","year":"2004","unstructured":"Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D\u2019arrigo, C., Calamoneri, F., et al. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14(1), 39\u201347.","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"1723_CR14","first-page":"218","volume-title":"Clinical Global Impression (CGI). ECDEU assessment manual for psychopharmacology. National Institute of Mental Health","year":"1976","unstructured":"Guy, W. (Ed.). (1976a). Clinical Global Impression (CGI). ECDEU assessment manual for psychopharmacology. National Institute of Mental Health (pp. 218\u2013222). Rockville, Maryland: Welfare publication."},{"key":"1723_CR15","first-page":"537","volume-title":"AIMS. Abnormal Involuntary Movement Scale. ECDEU Assessment for Psychopharmacology. Rev. Ed, National Institute of Mental Health","year":"1976","unstructured":"Guy, W. (Ed.). (1976b). AIMS. Abnormal Involuntary Movement Scale. ECDEU Assessment for Psychopharmacology. Rev. Ed, National Institute of Mental Health (pp. 537\u2013543). Rockville, Maryland: Welfare publication."},{"key":"1723_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13550280590900553","volume":"11","author":"JE Libbey","year":"2005","unstructured":"Libbey, J. E., Sweeten, T. L., McMahon, W. M., & Fujinami, R. S. (2005). Review: Autistic disorder and viral infections. Journal of Neurovirology, 11, 1\u201310.","journal-title":"Journal of Neurovirology"},{"issue":"2","key":"1723_CR18","first-page":"8","volume":"6","author":"JA Lieberman","year":"2004","unstructured":"Lieberman, J. A. (2004). Metabolic changes associated with antipsychotic use. Prim Care Campanion. Journal of Clinical Psychiatry, 6(2), 8\u201313.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"1723_CR19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1542\/peds.2007-1041","volume":"120","author":"C Limperopoulos","year":"2007","unstructured":"Limperopoulos, C., Bassan, H., Gauvreau, K., Robertson, R. L., Jr, Sullivan, N. R., Benson, C. B., et al. (2007). Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors? Pediatrics, 120(3), 584\u2013593.","journal-title":"Pediatrics"},{"issue":"2","key":"1723_CR20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","volume":"41","author":"RP Malone","year":"2002","unstructured":"Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., & Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2), 140\u2013147.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"4","key":"1723_CR21","first-page":"16","volume":"64","author":"CJ Mc Dougle","year":"2003","unstructured":"Mc Dougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescent with autism and conduct disorder. Journal of Clinical Psychiatry, 64(4), 16\u201325.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"1723_CR22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken, J. T., Mcgough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314\u2013321.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"1723_CR23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199804000-00014","volume":"37","author":"R Nicolson","year":"1998","unstructured":"Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 372\u2013376.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"1723_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","volume":"37","author":"GJ Pandina","year":"2007","unstructured":"Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367\u2013373.","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"7","key":"1723_CR25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tins.2006.05.010","volume":"29","author":"AM Persico","year":"2006","unstructured":"Persico, A. M., & Bourgeron, T. (2006). Searching for ways out of the autism maze: Genetic, epigenetic and environmental clues. Trends in Neurosciences, 29(7), 349\u2013358.","journal-title":"Trends in Neurosciences"},{"key":"1723_CR27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","volume":"163","author":"M Reyes","year":"2006","unstructured":"Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry, 163, 402\u2013410.","journal-title":"American Journal of Psychiatry"},{"key":"1723_CR28","unstructured":"Risperdal\u00ae Prescribing Information (revised 2012). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020272s065,020588s053,021444s041lbl.pdf ."},{"key":"1723_CR29","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"RUPP","year":"2005","unstructured":"RUPP. (2005). Research units on pediatric psychopharmacology autism network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6\u00a0months. American Journal of Psychiatry, 162, 1361\u20131369.","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"1723_CR30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","volume":"36","author":"L Scahill","year":"1997","unstructured":"Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children\u2019s yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844\u2013852.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"1723_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijdevneu.2004.12.012","volume":"23","author":"RT Schultz","year":"2005","unstructured":"Schultz, R. T. (2005). Developmental deficits in social perception in autism: The role of the amygdala and fusiform face area. International Society for Developmental Neuroscience, 23, 125\u2013141.","journal-title":"International Society for Developmental Neuroscience"},{"issue":"5","key":"1723_CR32","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634\u2013e641.","journal-title":"Pediatrics"},{"key":"1723_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson, G. M., & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum, 212, 11\u201319.","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"issue":"7","key":"1723_CR34","doi-asserted-by":"crossref","first-page":"A412","DOI":"10.1289\/ehp.114-a412","volume":"114","author":"M Szpir","year":"2006","unstructured":"Szpir, M. (2006). Tracing the origins of autism: A spectrum of new studies. Environmental Health Perspectives, 114(7), A412\u2013A418.","journal-title":"Environmental Health Perspectives"},{"issue":"7","key":"1723_CR35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/11531730-000000000-00000","volume":"49","author":"A Thyssen","year":"2010","unstructured":"Thyssen, A., Vermeulen, A., Fuseau, E., Fabre, M., & Mannaert, E. (2010). Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clinical Pharmacokinetics, 49(7), 465\u2013478.","journal-title":"Clinical Pharmacokinetics"},{"issue":"11","key":"1723_CR36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","volume":"44","author":"PW Troost","year":"2005","unstructured":"Troost, P. W., Lahuis, B. E., Steenhuis, M. P., Ketelaars, C. E. J., Buitelaar, J. K., & Van England, H. (2005). Long-trem effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry, 44(11), 1137\u20131144.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"8","key":"1723_CR37","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","volume":"61","author":"A Tschoner","year":"2007","unstructured":"Tschoner, A., Engl, J., Lamier, M., Kaser, S., Rettenbacher, M., Fleischhacker, J. R., et al. (2007). Review: Metabolic side effect of antipsychotic medication. International Journal of Clinical Practice, 61(8), 1356\u20131370.","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"1723_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.3.e34","volume":"110","author":"A Turgay","year":"2002","unstructured":"Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110(3), 1\u201312.","journal-title":"Pediatrics"}],"container-title":["Journal of Autism and Developmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10803-012-1723-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10803-012-1723-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10803-012-1723-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:51:29Z","timestamp":1559263889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10803-012-1723-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1007\/s10803-012-1723-5","relation":{},"ISSN":["0162-3257","1573-3432"],"issn-type":[{"value":"0162-3257","type":"print"},{"value":"1573-3432","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}